Sophie Iochmann

Sophie Iochmann

Auto-generated profile, based on publicly available information

Sophie Iochmann

Equipe Associée INRA d'Immunologie Parasitaire, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, France

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 1999 in Circulation
Verified
Journal Article
Closed access
PDF file
CPClaire Pouplard
Claire Pouplard
MMMarc-Antoine May
Marc-Antoine May
SISophie Iochmann
Sophie Iochmann
JAJean Amiral
Jean Amiral
AVAnne-Marie Vissac
Anne-Marie Vissac
YGYves Gruel
Yves Gruel
Background —Cardiopulmonary bypass (CPB) induces platelet activation with release of platelet factor 4 (PF4), and patients are exposed to high doses of heparin (H). We investigated whether this contributes to the development of antibodies to H-PF4 and heparin-induced thrombocytopenia (HIT). Methods and Results —CPB was performed with unfractionated heparin (UFH) in 328 patients. After surgery, patients received UFH (calcium heparin, 200 IU · kg −1 · d −1 ) (group 1, n=157) or low-molecular-weight heparin (LMWH, Dalteparin, 5000 IU once daily) (group 2, n=171). Eight days after surgery, antibodies to H-PF4 were present in 83 patients (25.3%), 46 in group 1 and 37 in group 2 ( P =0.12). Most patients (61%) had IgG1 to H-PF4, but only 8 samples with antibodies induced platelet activation with positive results on serotonin release assay. HIT occurred in 6 patients in group 1, but no thrombocytopenia was observed in subjects receiving LMWH, although 2 had high levels of antibodies with positive serotonin release assay results. When antibodies to H-PF4 were present, mean platelet counts were lower only in patients with FcγRIIA R/R 131 platelets. Conclusions —These results provide evidence that the development of antibodies to H-PF4 after CPB performed with UFH is not influenced by the postoperative heparin treatment. The antibodies associated with high risk of HIT are mainly IgG1, which is present at high titers in the plasma of patients continuously treated with UFH.

1 January 2007 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
Sebastien RogerSebastien Roger
Sebastien Roger
JRJérôme Rollin
Jérôme Rollin
ABAurélia Barascu
Aurélia Barascu
PBPierre Besson
Pierre Besson
PRPierre-Ivan Raynal
Pierre-Ivan Raynal
JGJean-Yves Le Guennec
Jean-Yves Le Guennec

15 May 2001 in Blood
Verified
Journal Article
Open access
CPClaire Pouplard
Claire Pouplard
SISophie Iochmann
Sophie Iochmann
BRBenoit Renard
Benoit Renard
OHOlivier Herault
Olivier Herault
PCPhilippe Colombat
Philippe Colombat
YGYves Gruel
Yves Gruel
The pathogenesis of thrombosis in heparin-induced thrombocytopenia (HIT) was studied by investigating whether antibodies to heparin-platelet factor 4 (H-PF4) induced tissue factor (TF) synthesis by monocytes. Plasma from 5 patients with HIT containing IgG to H-PF4 was incubated with peripheral blood mononuclear cells without or with purified PF4 and heparin. Significant TF-dependent procoagulant activity (PCA) expressed by monocytes, measured with a factor Xa-based chromogenic assay, was induced after incubation of each HIT plasma sample. This monocyte PCA required the presence of PF4 and was inhibited by high concentrations of heparin. Furthermore, purified HIT IgG added to whole blood with PF4 and heparin also provoked significant synthesis of TF mRNA by monocytes, demonstrated by RT-PCR, and this effect was not observed with normal IgG. These findings strongly support the hypothesis that antibodies to PF4 developed in HIT trigger the production of tissue factor by monocytes, and this effect could account in vivo for hypercoagulability and thrombotic complications in affected patients.

1 May 2007 in Lung Cancer
Verified
Journal Article
Closed access
JRJérôme Rollin
Jérôme Rollin
SRSandra Régina
Sandra Régina
PVPatrick Vourc’h
Patrick Vourc’h
SISophie Iochmann
Sophie Iochmann
CBClaire Bléchet
Claire Bléchet
YGYves Gruel
Yves Gruel

1 May 1999 in Vaccine
Verified
Journal Article
Closed access
SSSerge Sagodira
Serge Sagodira
DBDominique Buzoni-Gatel
Dominique Buzoni-Gatel
SISophie Iochmann
Sophie Iochmann
MNMuriel Naciri
Muriel Naciri
DBDaniel Bout
Daniel Bout

1 February 2005 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
JRJ Rollin
J Rollin
SIS Iochmann
S Iochmann
CBC Bléchet
C Bléchet
Florent HubéFlorent Hubé
Florent Hubé
SRS Régina
S Régina
YGYves Gruel
Yves Gruel
Tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-type serine proteinase inhibitor that inhibits plasmin-dependent activation of several metalloproteinases. Downregulation of TFPI-2 could thus enhance the invasive potential of neoplastic cells in several cancers, including lung cancer. In this study, TFPI-2 mRNA was measured using a real-time PCR method in tumours of 59 patients with non-small-cell lung cancer (NSCLC). Tumour TFPI-2 mRNA levels appeared well correlated with protein expression evaluated by immunohistochemistry and were 4–120 times lower compared to those of nonaffected lung tissue in 22 cases (37%). Hypermethylation of the TFPI-2 gene promoter was demonstrated by restriction enzyme-polymerase chain reaction in 12 of 40 cases of NSCLC (30%), including nine of 17 for whom tumour TFPI-2 gene expression was lower than in noncancerous tissue. In contrast, this epigenetic modification was shown in only three of 23 tumours in which no decrease in TFPI-2 synthesis was found (P=0.016). Decreased TFPI-2 gene expression and hypermethylation were more frequently associated with stages III or IV NSCLC (eight out of 10, P=0.02) and the TFPI-2 gene promoter was more frequently hypermethylated in patients with lymph node metastases (eight out of 16, P=0.02). These results suggest that silencing of the TFPI-2 gene by hypermethylation might contribute to tumour progression in NSCLC.